Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“I often get the question, “What exactly is precision medicine?”
In short, it means personalizing treatment to each patient based on biomarkers. The question that naturally follows: “what are biomarkers?”
In cancer care, they are the specific genes, proteins or other molecular markers that are unique to a person’s cancer. By testing for these, we can choose treatments that fit both the patient and their disease.
Biomarker testing is a game changer for how AstraZeneca tackles cancer, which is why it’s critical that we make it accessible to every patient in every zip code.”
More posts featuring Mohit Manrao on OncoDaily.